DOCSLIB.ORG

Effects of Orchiectomy, Alone Or in Combination with Testosterone, and Cyproterone Acetate on Exocrine Pancreatic Carcinogenesis in Rats and Hamsters

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Orchiectomy, Alone Or in Combination with Testosterone, and Cyproterone Acetate on Exocrine Pancreatic Carcinogenesis in Rats and Hamsters International Journal ofPancreatology, vol, l 1, no. 2, April 1992 Copyright 1992 by The Humana Press Inc, All rights of any nature whatsoever re~sexved. 0169-4197/92/11:137-146/$2,00 Effects of Orchiectomy, Alone or in Combination with Testosterone, and Cyproterone Acetate on Exocrine Pancreatic Carcinogenesis in Rats and Hamsters M. Meijers, 1 C. J. T. Visser,' J. G. M. Klijn, 2 S. W. J. Lamberts, j A. van Garderen-Hoetmer, x E 1t. de Jong," J. A. Foekens, z and R. A. Woutersen *'1 JDepartment of Biological Toxicology, TNO Toxicology and Nutrition Institute, Zeist, The Netherlands; ~Division of Endocrine Oncology (Department of Medical Oncology), Dr. Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands; JDepartment of Internal Medicine, Erasmus University, Rotterdam, The Netherlands; and 4Department of Endocrinology and Reproduction, Erasmus University, Rotterdam, The Netherlands Summary The results of a previous 4-rot study in azaserine-treated rats and BOP-treated hamsters indicated that orchiectomy inhibited pancreatic growth and development of putative preneoplastic lesions in the exo- crine pancreas of rats but not hamsters. This 12-rot study was carried out to investigate the effects of orchiectomy, alone and in combination with testosterone, and of treatment with cyproterone acetate on pancreatic carcinogenesis in azaserine-treated rats and BOP-treated hamsters. Treatment started 4 mo after injection of the carcinogen~ In orchiectomized rats, pancreatic wt was lower than in controls, whereas pancreatic wt of orchiectomized rats treated with testosterone was similar to that of controls. Both orchiectomy and cyproterone acetate caused a decrease in body wt gain and had an inhibitory effect on pancreatic carcinogenesis. Testosterone treatment did not influence the inhibitory effects of orchiectomy on body wt gain and on pancreatic carcinogenesis. In hamsters, neither orchiectomy, alone or in combina- tion with testosterone, nor cyproterone acetate (CA) affected pancreatic growth or pancreatic carcinogenesis. This study indicates that testosterone plays a minor role in the development of pancreatic tumors induced in rats by azaserine but not in that of pancreatic tumors induced in hamsters by BOP. Key Words: Exocrine pancreas; cancer; rat; hamster; orchiectomy; testosterone; cyproterone acetate~ Introduction (1,2). Apart from life-style factors, hormonal factors have been suggested to be responsible for this sex In most countries, the age-adjusted incidence of difference. A higher number of atypical acinar cell pancreatic cancer is higher in men than in women nodules (AACN) and a higher incidence of pancre- Received (September 30, 1991); Revised (October 18, 1991); atic neoplasms have been found in male than in Accepted (November 12, 1991) female rats treated with azaserine (3). Using the AT- *Author to whom all correspondence and reprint requests Pase staining, Bax et al. found that acidophilic loci in should be addressed at: Department of Biological Toxicology, male rats were consistently larger (1.75 times) than TNO Toxicology and Nutrition Instituter PO Box 360, 3700 AJ Zeist, The Netherlands in females and concluded that the sex-related differ- 137 138 Meijers et at. ence in the numbers of acidophilic AACN induced in pancreatic carcinogenesis in hamsters and rats during rat pancreas by azaserine may be ascribed to the dif- a long-term treatment period of 8 mo started 4 mo ficulty in detecting small acidophilic foci in hema- after tumor induction. toxylin and eosin (H&E)-stained sections (4). In rats, the inhibitory effect of castration on growth of Materials and Methods azaserine-induced AACN has been ascribed to decreased serum testosterone levels (5-7). The inhibitory effect Animals and Tumor Induction of castration, however, was not influenced by treat- Two hundred male weanling SPF albino Wistar Bor ment with testosterone. In a previous 4-too study with rats (WISW, Cpb) were obtained from F. Winkelmann azaserine-treated rats, we also found an inhibitory (FRG) and injected ip four times with 30 mg effect of orchiectomy on the development of AACN, azaserine/kg body wt at 19, 26, 33, and 103 d of which was accompanied by a significant decrease in age. One hundred and forty male Syrian golden absolute but not relative pancreatic wt. From the hamsters (Charles River Wiga, Sulzfeld, FRG) were results of that study, we concluded that, apart from each injected sc, once weekly, with 20 mg BOP/kg testosterone, nutritional status and pancreatic growth body wt at 6, 7, and 8 wk of age according to an may play a highly significant role in the development injection protocol described previously (19). BOP of putative pancreatic preneoptastic lesions (8). (Ash Stevens, Inc., 5861 John C. Lodge Freeway, No consistent variations have been found in inci- Detroit, MI 48202) and azaserine (Calbiochem- dence of pancreatic (pre)neoplastic lesions in male Behring Corp., LaJolla, CA) were dissolved freshly and female hamsters induced by sc injections with in 0.9% NaC1 solution. The animals were allocated nitrosamine derivatives. Pour et al. did not find a by a computerized randomization procedure to four difference between male and female hamsters in the different groups, each of which consisted of either 50 incidence of pancreatic tumors after injection with rats or 35 hamsters. The rats were housed in stain- N-nitrosobis (2-oxopropyl)amine (BOP) (9,10). less-steel cages, fitted with wiremesh floors and fronts, Kokkinakis, on the contrary, found that tumor inci- and the hamsters in macrolon cages on softwood bed- dence, multiplicity, and Size were generally larger in ding. The animals were kept under standard labora- female than in male hamsters after administration of tory conditions, five animals per cage, and fed a high N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine fat/high protein diet during the first 4 mo of the study (HPOP) (11). Pancreatic (H2T) ceils transplanted in in order to enhance the development of ductular lesions hamster cheek pouches developed faster into ductat in the exocrine pancreas. adenocarcinomas in intact females and castrated males than in ovariectomized females and intact males, Treatment respectively, pointing to an inhibitory effect of tes- tosterone or an enhancing effect of estrogen (12). In order to mimic the human situation, treatment SchaUy and co-workers, however, found that the started when early (pre)neoplastic lesions had already development of pancreatic tumors induced in male developedin the pancreas, i.e. 4 mo after the last injec- hamsters by BOP was inhibited by medical or surgi- tion with carcinogen. The animals received one of the cal castration (13-18). Furthermore, in a previously following treatments: group A, saline (controls); group conducted 4-mo study, we did not find any effect of B, surgical castration; group C, surgical castration plus castration or Luteinizing Hormone Releasing Hor- testosterone; and group D, CA. Testosterone was mone (LHRH) treatment on the development of early administered as testosterone proprionate by silastic (pre)neoplastic lesions induced in hamster pancreas implants as described previously (20). Rats received by BOP (8). This experiment was performed to evalu- two, 3-cm implants per animal, and hamsters, in view ate the effects of castration, either alone or in combi- of lower body wt, received one implant per animal nation with testosterone h-eatment, and of treatment once at start of treatment. Cyproterone acetate was with the antiandrogen cyproterone acetate (CA) on used as Androcur tablets (50 rag) dispersed in tap International Journal of Pancreatology Volume 11, 1992 Sex Steroid Hormones 139 water. The animals were given CA by gavage daily at using initial body wt as covariable. The number of a dose of 50 mg/kg, as described previously (21). borderline and other (pre)neoplasfic lesions were sta- During treatment, the animals were fed the TNO tistically evaluated with a generalized linear model Institute's basal diet, which is Iow in fat (5%) and (26). With such a model, the effects of type of treat- compounded from natural feed ingredients. Body wt rnent (control, surgical castration, surgical castration were recorded weekty during the first 3 mo and once plus testosteror~, or CA) were assessed. For rats, the a month during the rest of the experiment. The gen- influence of time of sacrifice (interim kill, terminal eral condition and behavior of the animals were autopsy) and possible interaction between type of checked daily. treatment and time of sacrifice were assessed as well. A Poisson error distribution was used for evaluation of Autopsy and Histological Analysis the lesions. In rats, an interim kill was performed on 20 ani- Evaluation of the prevalence (incidence) of tu- mals of each group after 4 mo of treatment. Terminal mors (terminal autopsy animals only) was done with autopsy on rats and hamsters was performed after 8 a generalized linear model. The difference with the mo of treatment on days 371 (rats), and 363 and 364 model used for lesions was the error distribution. (hamsters) after the last injection with carcinogen. The With respect to prevalence, the binomial distribu- animals were anesthetized by ether, exsanguinated by tion was appropriate. cannulating the abdominal aorta, autopsied, and then Endocrine Investigations examined for gross pathological changes. From each animal, the pancreas, liver, testes (if present), adrenals, Blood sampling for hormone estimations was per- and pituitary were excised and weighed. These formed at the start of the treatment period (n = 19- organs were fixed in 10% buffered formalin. The 20), after 4 mo (n = 10) and after 8 mo (n = 10) of pancreata were completely processed for microscopy treatment at the end of the experiment by exsang- by conventional methods, step-sectioned at 5 ~m uination. In groups of five animals, blood sampling (about 5 per pancreas), stained with H&E, and exam- was also performed after 2 and 6 mo by orbita ined by light microscopy. About 200 mm2 of pancre- punctions.
Load more

Recommended publications
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Periodic Hypokalaemic Paralysis, Adrenal Adenoma, and Normal Colonic Transport of Sodium and Potassium
    Gut: first published as 10.1136/gut.14.6.478 on 1 June 1973. Downloaded from Gut, 1973, 14, 478-484 Periodic hypokalaemic paralysis, adrenal adenoma, and normal colonic transport of sodium and potassium PETER RICHARDS1, M. B. S. JONES, AND W. S. PEART From the Medical Unit, St Mary's Hospital Medical School, London SUMMARY A 47-year-old woman was cured of hypokalaemia and recurrent paralysis by the excision of an adrenal adenoma. Hypertension was initially ameliorated but was not cured. Suppression of plasma renin activity was abolished when the adenoma was excised. Repeated measurement of plasma corticosteroids before operation showed a slight increase in aldosterone and normal plasma concentrations of deoxycorticosterone, corticosterone, and cortisol. No evidence of excess mineralo- corticoid was obtained from measurement of the electrolyte composition of colonic fluid or of rectal potential difference, although both these variables responded normally to salt depletion and exogenous aldosterone. The diagnostic importance of the paradoxically normal colonic measure- ments is emphasized and the possibility is considered that the adenoma may have secreted an unidentified hormone. http://gut.bmj.com/ The colon normally responds to excessive plasma not escape from the action of these hormones. One concentrations of aldosterone, corticosterone, and patient has been described in whom colonic sodium deoxycorticosterone by modifying faecal fluid so fluxes were apparently normal and were unchanged that the concentration of sodium is very low and that by the excision of an aldosterone-secreting adrenal of potassium high (Wrong, Morrison, and Hurst, adenoma; potassium influx was nevertheless in- 1961; Wrong and Metcalfe-Gibson, 1965; creased and returned to normal after operation Richards, on September 29, 2021 by guest.
    [Show full text]
  • The Role of Highly Selective Androgen Receptor (AR) Targeted
    P h a s e I I S t u d y o f I t r a c o n a z o l e i n B i o c h e m i c a l R e l a p s e Version 4.0: October 8, 2014 CC# 125513 CC# 125513: Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse Investigational Agent: Itraconazole IND: IND Exempt (IND 116597) Protocol Version: 4.0 Version Date: October 8, 2014 Principal Investigator: Rahul Aggarwal, M.D., HS Assistant Clinical Professor Division of Hematology/Oncology, Department of Medicine University of California San Francisco 1600 Divisadero St. San Francisco, CA94115 [email protected] UCSF Co-Investigators: Charles J. Ryan, M.D., Eric Small, M.D., Professor of Medicine Professor of Medicine and Urology Lawrence Fong, M.D., Terence Friedlander, M.D., Professor in Residence Assistant Clinical Professor Amy Lin, M.D., Associate Clinical Professor Won Kim, M.D., Assistant Clinical Professor Statistician: Li Zhang, Ph.D, Biostatistics Core RevisionHistory October 8, 2014 Version 4.0 November 18, 2013 Version 3.0 January 28, 2013 Version 2.0 July 16, 2012 Version 1.0 Phase II - Itraconazole Page 1 of 79 P h a s e I I S t u d y o f I t r a c o n a z o l e i n B i o c h e m i c a l R e l a p s e Version 4.0: October 8, 2014 CC# 125513 Protocol Signature Page Protocol No.: 122513 Version # and Date: 4.0 - October 8, 2014 1.
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S
    Evidence Synthesis Number 180 Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-00009-I, Task Order No. 7 Prepared by: Pacific Northwest Evidence-Based Practice Center Oregon Health & Science University Mail Code: BICC 3181 SW Sam Jackson Park Road Portland, OR 97239 www.ohsu.edu/epc Investigators: Heidi D. Nelson, MD, MPH Rongwei Fu, PhD Bernadette Zakher, MBBS Marian McDonagh, PharmD Miranda Pappas, MA L.B. Miller, BA Lucy Stillman, BS AHRQ Publication No. 19-05249-EF-1 January 2019 This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]
  • Treatment of Cushing's Disease
    D CUEVAS-RAMOS and M FLESERIU Treatment of Cushing’s disease 223:2 R19–R39 Review Treatment of Cushing’s disease: a mechanistic update Daniel Cuevas-Ramos1,2 and Maria Fleseriu3 1Department of Medicine, Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, California, USA Correspondence 2Neuroendocrinology Clinic, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias should be addressed Me´ dicas y Nutricio´ n Salvador Zubira´ n, Mexico City, Mexico to M Fleseriu 3Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health & Science Email University, 3181 SW Sam Jackson Park Road (BTE 472), Portland, Oregon 97239, USA fl[email protected] Abstract Cushing’s disease (CD) is characterized by an ACTH-producing anterior corticotrope pituitary Key Words adenoma. If hypothalamus–pituitary–adrenal (HPA) axis physiology is disrupted, ACTH " cortisol secretion increases, which in turn stimulates adrenocortical steroidogenesis and cortisol " Cushing’s disease production. Medical treatment plays an important role for patients with persistent disease " ACTH after surgery, for those in whom surgery is not feasible, or while awaiting effects of " pasireotide radiation. Multiple drugs, with different mechanisms of action and variable efficacy and " mifepristone tolerability for controlling the deleterious effects of chronic glucocorticoid excess, are " ketoconazole available. The molecular basis and clinical data for centrally acting drugs, adrenal " LCI699 steroidogenesis inhibitors, and glucocorticoid receptor antagonists are reviewed, as are " cabergoline potential novel molecules and future possible targets for CD treatment. Although progress has been made in the understanding of specific corticotrope adenoma receptor physiology Journal of Endocrinology and recent clinical studies have detected improved effects with a combined medical therapy approach, there is a clear need for a more efficacious and better-tolerated medical therapy for patients with CD.
    [Show full text]
  • Use of Aromatase Inhibitors in Breast Carcinoma
    Endocrine-Related Cancer (1999) 6 75-92 Use of aromatase inhibitors in breast carcinoma R J Santen and H A Harvey1 Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA 1Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA (Requests for offprints should be addressed to R J Santen) Abstract Aromatase, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to estrogens, is the major mechanism of estrogen synthesis in the post-menopausal woman. We review some of the recent scientific advances which shed light on the biologic significance, physiology, expression and regulation of aromatase in breast tissue. Inhibition of aromatase, the terminal step in estrogen biosynthesis, provides a way of treating hormone-dependent breast cancer in older patients. Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks. Newer agents are considerably more selective, more potent, less toxic and easier to use in the clinical setting. This article reviews the clinical data supporting the use of the potent, oral competitive aromatase inhibitors anastrozole, letrozole and vorozole and the irreversible inhibitors 4-OH andro- stenedione and exemestane. The more potent compounds inhibit both peripheral and intra-tumoral aromatase. We discuss the evidence supporting the notion that aromatase inhibitors lack cross- resistance with antiestrogens and suggest that the newer, more potent compounds may have a particular application in breast cancer treatment in a setting of adaptive hypersensitivity to estrogens. Currently available aromatase inhibitors are safe and effective in the management of hormone- dependent breast cancer in post-menopausal women failing antiestrogen therapy and should now be used before progestational agents.
    [Show full text]
  • Clinical Trial of Multiple Endocrine Therapy For
    [CANCER RESEARCH (SUPPL.) 42, 3458s-3460s, August 1982] 0008-5472/82/0042-OOOOS02.00 Clinical Trial of Multiple Endocrine Therapy for Metastatic and Locally Advanced Breast Cancer with Tamoxifen-Aminoglutethimide- Danazol Compared to Tamoxifen Used Alone1 Trevor J. Powles, C. Gordon, and R. C. Coombes Medical Breast Unit, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, England Abstract Multiple-endocrine therapy with combinations of various This paper reports a controlled randomized clinical trial types of treatment has not been evaluated properly in spite of which compared treatment of advanced breast cancer with the success of individual types of hormone treatment. This tamoxifen to treatment with a combination of TAD.2 paper reports the early results of a randomized controlled clinical trial comparing tamoxifen (10 mg 2 times/day)-amino- Patients and Methods glutethimide (250 mg 3 times/day)-danazol (100 mg 3 times/ Between September 1979 and April 1981, 122 patients with as day)-hydrocortisone (20 mg 2 times/day) (TAD) with tamoxifen sessable metastatic or locally advanced breast cancer have been (10 mg 2 times/day). randomized to receive either tamoxifen (10 mg twice/day) or a com Analysis of the first 107 assessable patients indicates objec bination of tamoxifen (10 mg twice/day), aminoglutethimide (250 mg tive response (criteria of the International Union Against Can 3 times/day), danazol (100 mg 3 times/day), and hydrocortisone (20 cer) in 33% of patients receiving tamoxifen versus 50% of mg twice/day). All patients were at least 1 year postmenopausal, with patients receiving TAD. Duration of response to TAD is identical histologically confirmed breast cancer and with a life expectancy of at to duration of response to tamoxifen alone.
    [Show full text]
  • Labeling Text Or Submitted Document Name: Draft Labeling (With Or Without Minor Editorial Revisions Included in the Letter)
    DOCUMENT INFORMATION PAGE This page is for FDA internal use only. Do NOT send this page with the letter. Application #(s): NDA 20-726/S-008 Document Type: NDA Letters Document Group: NDA Supplement Approval Letters Approval, effective on date of letter, based on enclosed labeling text or submitted Document Name: draft labeling (with or without minor editorial revisions included in the letter). Shortcut ID Code: SNDA-I1 COMIS Decision Code AP Drafted by: AMS/12-31-02 Revised by: Initialed by: Pease/1-13-03 Sridhara/1-14-03 Chen/1-14-03 Cohen/1-14-03 Johnson/1-14-03 Finalized: AMS/1-15-03 Filename: DFS Key Words: Notes: Version: 12/18/2002 END OF DOCUMENT INFORMATION PAGE The letter begins on the next page. DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 NDA 20-876/S-008 Novartis Pharmaceuticals Corporation One Health Plaza, Building 105/2W200 Hanover, New Jersey 07936-1080 Attention: Arlene Wolny, Associate Director Drug Regulatory Affairs Dear Ms. Wolny: Please refer to your supplemental new drug application dated March 15, 2002, received March 18, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Femara (letrozole) tablets, 2.5 mg. We acknowledge receipt of your submissions dated November 15, 2002 and January 2, 2003. This supplemental new drug application provides for updating the safety and efficacy data for Femara for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer and includes revisions to the Clinical Studies, Precautions, and Adverse Reactions sections of the labeling.
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]
  • Are We Missing the Issues That Really Matter?
    A mixed method study on the prevalence, severity and experience of genitourinary symptoms and the impact on sexual function and QoL in postmenopausal women on endocrine therapy for early breast cancer MARIANA S. SOUSA ARE WE MISSING THE ISSUES THAT REALLY MATTER? 1 ARE WE MISSING THE ISSUES THAT REALLY MATTER? A mixed method study on the prevalence, severity and experience of genitourinary symptoms and the impact on sexual function and quality of life in postmenopausal women on endocrine therapy for early breast cancer Mariana de Souza e Sousa A thesis in fulfillment of the requirements for the degree of Doctor of Philosophy Prince of Wales Clinical School Faculty of Medicine University of New South Wales Australia 2015 iii PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: de Souza e Sousa First name: Mariana Other name/s: N/A Abbreviation for degree as given in the University calendar: PhD School: Prince of Wales Clinical School Faculty: Medicine Title: Are we missing the issues that really matter? A mixed-method study on the prevalence, severity and experience of genitourinary symptoms and the impact on sexual function and Qol in postmenopausal women on endocrine therapy for early breast cancer Abstract 350 words maximum: (PLEASE TYPE) The underlying hypothesis of this PhD Is that the negative Impact of adjuvant endocrine therapy on genitourinary symptoms In postmenopausal women with early breast cancer has been underestimated In clinical trials and that there are a myriad of genitourinary symptoms related to or exacerbated by endocrine therapies that are commonly not reported by women to their oncologists.
    [Show full text]
  • Clinical Protocol : Topotecan Plus Cisplatin Induction Followed By
    UCI 03-16 Revised Version date 04/25/2011 Clinical Protocol UCI 03-16: Phase II Chemoprevention Trial - Anastrozole in the DCIS and early invasive breast cancer in postmenopausal women 1.0 OBJECTIVE 1.1 To assess the efficacy in terms of reduction in Ki-67(as a surrogate endpoint to breast cancer risk reduction) in patients treated with anastrozole. 1.2 To measure the histopathological response and correlate the degree of histopathological response with the degree of Ki-67 response. 1.3 To compare pretreatment vascular density with post treatment vascular density using MRI 1.4 To compare pretreatment markers of angiogenesis with post treatment marker of angiogenesis. 1.5 To correlate MR imaging response to markers of angiogenesis response. 1.6 To correlate ER, Ki-67, angiogenesis markers and MRI response to histopathological changes 2.0 BACKGROUND A. SPECIFIC AIMS Breast cancer is a genetically heterogeneous disease. Hormone receptor expression occurs in the majority of postmenopausal breast cancer and defines the subset that can be treated and prevented with hormone modulators. Hormone modulators include antiestrogen like tamoxifen and aromatase inhibitor that block the formation of estrogens in the adrenal glands and peripheral tissue. Hormone modulators have been established in treatment of invasive breast cancer. These agents not only been established as treatment for breast cancer but also have demonstrated efficacy as chemopreventive agents. Tamoxifen has been established as a chemopreventive agent in reducing the development of breast cancer in patients who are at high risk of developing breast cancer. Intriguing results have been obtained in the reduction of breast cancer event rates in established breast cancer patients treated with anastrozole as compared to patients treated with tamoxifen, providing the first glimpse of its efficacy as a chemopreventive agent.
    [Show full text]